Literature DB >> 29785700

The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.

L Zhang1, X Fang1, L Li2, R Liu1, C Zhang3, H Liu4, M Tan5, G Yang6.   

Abstract

PURPOSE: The diagnosis of polycystic ovary syndrome (PCOS) is based on a combination of various clinical phenotypes in each patient. However, insulin resistance (IR) and dysmetabolism are not included in the diagnostic criteria of PCOS. Therefore, the definition of PCOS is controversial. The objective of this study is to investigate whether some PCOS phenotypes can be predicted by a circulating biomarker related to IR and metabolic dysfunction in PCOS women.
METHODS: One hundred and seventeen women with PCOS and 95 healthy women were recruited for this study. All individuals were assessed by the phenotypic and metabolic characteristics related to PCOS. A euglycemic-hyperinsulinemic clamp was performed to assess insulin sensitivity. Circulating irisin concentrations were determined with ELISA.
RESULTS: In our PCOS cohort, 65.8% of individuals were found to have hyperandrogenism. 83.8% had chronic oligoanovulation, and 80.3% of subjects showed polycystic ovaries. According to the diagnostic criteria of PCOS, 30.8% of PCOS subjects were diagnosed with the classic phenotype. In addition, 65.8% of PCOS women had insulin resistance. Serum irisin levels were significantly higher in PCOS women compared with healthy women. However, PCOS women with a normoandrogenic phenotype had similar circulating irisin levels as healthy women. PCOS women with the normoandrogenic phenotype had a low homeostasis model assessment of insulin resistance (HOMA-IR) and higher M-values than PCOS women with other phenotypes. Circulating irisin levels were associated with hyperandrogenism, but not with oligoanovulation or PCO morphology.
CONCLUSIONS: Circulating irisin may allow physicians to establish which women merit screening by a biomarker for PCOS.

Entities:  

Keywords:  Euglycemic–hyperinsulinemic clamp; Insulin resistance; Irisin; PCOS

Mesh:

Substances:

Year:  2018        PMID: 29785700     DOI: 10.1007/s40618-018-0902-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test.

Authors:  M Albareda; J Rodríguez-Espinosa; M Murugo; A de Leiva; R Corcoy
Journal:  Diabetologia       Date:  2000-12       Impact factor: 10.122

Review 2.  The insulin resistance syndrome: definition and dietary approaches to treatment.

Authors:  Gerald M Reaven
Journal:  Annu Rev Nutr       Date:  2005       Impact factor: 11.848

3.  Circulating irisin in relation to insulin resistance and the metabolic syndrome.

Authors:  Kyung Hee Park; Lesya Zaichenko; Mary Brinkoetter; Bindiya Thakkar; Ayse Sahin-Efe; Kyoung Eun Joung; Michael A Tsoukas; Eleni V Geladari; Joo Young Huh; Fadime Dincer; Cynthia R Davis; Judith A Crowell; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

4.  Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.

Authors:  Catherine Marin DeUgarte; Alfred A Bartolucci; Ricardo Azziz
Journal:  Fertil Steril       Date:  2005-05       Impact factor: 7.329

Review 5.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

7.  Lower circulating irisin is associated with type 2 diabetes mellitus.

Authors:  Jian-Jun Liu; Melvin D S Wong; Wan Ching Toy; Clara S H Tan; Sylvia Liu; Xiao Wei Ng; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim
Journal:  J Diabetes Complications       Date:  2013-04-22       Impact factor: 2.852

8.  Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.

Authors:  Enrico Carmina; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2004-09       Impact factor: 7.329

9.  Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome.

Authors:  Mehmet Calan; Ozgur Yilmaz; Tuncay Kume; Gokcen Unal Kocabas; Pinar Yesil Senses; Yasar Mehmet Senses; Muzaffer Temur; Ozlem Gursoy Calan
Journal:  Endocrine       Date:  2016-02-01       Impact factor: 3.633

10.  Modulation of insulin activities by leptin.

Authors:  B Cohen; D Novick; M Rubinstein
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

View more
  9 in total

1.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

Review 2.  Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.

Authors:  Viktor V Smirnov; Narasimha M Beeraka; Dmitry Yu Butko; Vladimir N Nikolenko; Sergey A Bondarev; Evgeniy E Achkasov; Mikhail Y Sinelnikov; P R Hemanth Vikram
Journal:  Reprod Sci       Date:  2022-06-28       Impact factor: 2.924

Review 3.  Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome.

Authors:  Tara McDonnell; Leanne Cussen; Marie McIlroy; Michael W O'Reilly
Journal:  Ther Adv Endocrinol Metab       Date:  2022-07-18       Impact factor: 4.435

Review 4.  Recent advances in the understanding and management of polycystic ovary syndrome.

Authors:  Ana L Rocha; Flávia R Oliveira; Rosana C Azevedo; Virginia A Silva; Thais M Peres; Ana L Candido; Karina B Gomes; Fernando M Reis
Journal:  F1000Res       Date:  2019-04-26

5.  Association of metabolic syndrome components with circulating levels of cytokine clusters in young women.

Authors:  Xingrong Tan; Wenjing Hu; Shan Yang; Han Dai; Shangcheng Xu; Gangyi Yang; Ling Li; Shiguo Tang; Yi Wang
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

6.  Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).

Authors:  A Podfigurna; B Meczekalski; F Petraglia; S Luisi
Journal:  J Endocrinol Invest       Date:  2019-10-25       Impact factor: 5.467

7.  Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial.

Authors:  Cheng-Ming Ni; Wen-Long Huang; Yan-Min Jiang; Juan Xu; Ru Duan; Yun-Long Zhu; Xu-Ping Zhu; Xue-Mei Fan; Guo-An Luo; Yi-Ming Wang; Yan-Yu Li; Qing He; Lan Xu
Journal:  Trials       Date:  2020-02-11       Impact factor: 2.279

8.  The Associations Between Serum Concentrations of Irisin and Glucose-dependent Insulinotropic Polypeptide with Body Mass Index Among Women with and Without Polycystic Ovary Syndrome.

Authors:  Samira Behboudi-Gandevani; Mehdi Hedayati; Mohammad Ali Mansournia; Maryam Nazemipour; Maryam Rahmati; Fahimeh Ramezani Tehrani
Journal:  Int J Endocrinol Metab       Date:  2021-05-31

9.  Correlation of Homeostatic Model Assessment-Insulin Resistance, Anti-Mullerian Hormone, and BMI in the Characterization of Polycystic Ovary Syndrome.

Authors:  Anupama Bahadur; Neha Verma; Rajlaxmi Mundhra; Latika Chawla; Megha Ajmani; Modalavalasa Swetha Sri; Shivaani Arora
Journal:  Cureus       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.